KLRB1 and neoplasm: A recent study has discovered that the knockdown of KLRB1 or antibody-mediated blockade of CD161 enhances the ability of T cells to kill tumor cells (Mathewson et al., 2021), suggesting that the CD161-LLT1 pathway may serve as a potential target of immunotherapy for glioma.